Related Experiment Video
Updated: Apr 28, 2026

Characterization of Glycoproteins with the Immunoglobulin Fold by X-Ray Crystallography and Biophysical Techniques
Published on: July 5, 2018
Multiscale Computational Studies of PEG Chain Length Effects on HER2 mAb Fc Structure and Binding Energetics
Heather A Noriega1,2, Emmanuel O Akala2, Xiang Simon Wang1,2
1Artificial Intelligence and Drug Discovery (AIDD), Core Laboratory for District of Columbia Center of AIDS Research (DC CFAR), Washington, D.C. 20052, United States.
Abstract:
HER2 overexpression in breast cancer drives aggressive disease, treated clinically with monoclonal antibodies such as trastuzumab and pertuzumab. While effective, these therapies are limited by suboptimal pharmacokinetics and tumor penetration. Polyethylene glycol (PEG) conjugation can extend circulation half-life but may alter Fc-mediated interactions and receptor binding. Here, we used a multiscale computational framework to quantify PEGylation effects on the pertuzumab Fc domain. Structural models were generated with AlphaFold2, refined with RoseTTAFold2 to incorporate G0F-type glycans at Asn297, and site-specifically PEGylated via hydrazone linkages in UCSF ChimeraX. Aglycosylated control and PEGylated variants (1, 2, and 4 kDa) underwent 100 ns all-atom molecular dynamics simulations in GROMACS. Increasing PEG size produced stepwise RMSD elevations (1.1-13 nm) and hinge expansion (21.37-63.53 Å). RMSF analysis revealed domain-specific mobility shifts within the Fc region: CH2 flexibility in the control, CH3 mobility in the 1 and 2 kDa variants, and CH2/CH3 destabilization (>2.0 nm) in the 4 kDa system. Principal component analysis showed PC1 (45-70% variance) capturing hinge-closing and CH2 inward motion in controls, versus CH3 separation and CH2-CH3 displacement in PEGylated forms; the 4 kDa variant exhibited pronounced flexibility (PC2 ∼20 to 25%). Complementary backbone dihedral and hydrogen bond analyses showed localized torsional relaxation and a reduction in CH2-CH3 hydrogen bond occupancy in PEGylated systems, confirming the structural basis of hinge expansion. Vector projections indicated steric and entropic disruption of interdomain hydrogen bonds, suggesting reduced Fcγ receptor engagement. These results reveal PEG size-dependent structural perturbations, providing a molecular basis for diminished HER2 affinity and guiding rational design of PEGylated mAbs with optimized pharmacokinetics and preserved effector function.
Insights
Polyethylene glycol (PEG) conjugation alters the structure of pertuzumab, a HER2-targeted antibody, impacting its effectiveness. Larger PEG sizes cause significant structural changes, potentially reducing antibody binding and effector function for breast cancer treatment.
Area of Science:
- Biochemistry
- Structural Biology
- Computational Biology
Background:
- HER2 overexpression drives aggressive breast cancer, necessitating treatments like trastuzumab and pertuzumab.
- Current antibody therapies face limitations in pharmacokinetics and tumor penetration.
- Polyethylene glycol (PEG) conjugation can improve drug half-life but may affect antibody function.
Purpose of the Study:
- To computationally investigate the structural impact of PEGylation on the pertuzumab Fc domain.
- To quantify how different PEG sizes affect antibody pharmacokinetics and effector functions.
- To provide a molecular basis for designing improved PEGylated monoclonal antibodies.
Main Methods:
- Utilized a multiscale computational framework including AlphaFold2 and RoseTTAFold2 for structural modeling.
- Incorporated G0F-type glycans and performed site-specific PEGylation using UCSF ChimeraX.
- Conducted all-atom molecular dynamics simulations in GROMACS for control and PEGylated variants (1, 2, and 4 kDa).
- Analyzed structural changes using RMSD, RMSF, principal component analysis, and hydrogen bond analysis.
Main Results:
- Increasing PEG size led to stepwise increases in RMSD and hinge region expansion.
- PEGylation induced domain-specific mobility shifts, with larger PEG sizes causing CH2/CH3 destabilization.
- Principal component analysis revealed altered domain dynamics in PEGylated forms, particularly with 4 kDa PEG.
- Identified structural disruptions in interdomain hydrogen bonds, suggesting reduced Fc receptor engagement.
Conclusions:
- PEGylation introduces size-dependent structural perturbations in the pertuzumab Fc domain.
- These structural changes provide a molecular explanation for potentially diminished HER2 binding affinity.
- Findings guide the rational design of PEGylated monoclonal antibodies with optimized pharmacokinetics and preserved effector functions.
More Related Videos
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
06:50Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions
Published on: January 26, 2024